FACTOID # 4: Just 1% of the houses in Nevada were built before 1939.
 
 Home   Encyclopedia   Statistics   States A-Z   Flags   Maps   FAQ   About 
   
 
WHAT'S NEW
 

SEARCH ALL

FACTS & STATISTICS    Advanced view

Search encyclopedia, statistics and forums:

 

 

(* = Graphable)

 

 


Encyclopedia > Coronary thrombosis

Thrombosis is the formation of a clot or thrombus inside a blood vessel, obstructing the flow of blood through the circulatory system. Thromboembolism is a general term describing both thrombosis and its main complication: dislodgement of a clot and embolisation.

Contents

Causes

Classically, thrombosis is caused by abnormalities in one or more of the following (Virchow's triad):

  • The composition of the blood
  • Quality of the vessel wall
  • Nature of the blood flow

The formation of a thrombus is usually caused by an injury to the vessel's wall, either by trauma or infection, and by the slowing or stagnation of blood flow past the point of injury. Occasionally, abnormalities in coagulation are to blame. Intravascular coagulation follows, forming a structureless mass of red blood cells, leukocytes, and fibrin.


Types/classification

There are two distinct forms of thrombosis:

Embolisation

If a bacterial infection is present at the site of thrombosis, the thrombus may break down, spreading particles of infected material throughout the circulatory system (pyemia, septic embolus) and setting up metastatic abscesses wherever they come to rest. Without an infection, the thrombus may become detached and enter circulation as an embolus, finally lodging in and completely obstructing a blood vessel (an infarction). The effects of an infarction depend on where it occurs.


Most thrombi, however, become organized into fibrous tissue, and the thrombosed vessel is gradually recanalized.


See also

See also:


Health science - Medicine - Hematology
Hematological malignancy and White blood cells
Lymphoma (Hodgkin's disease, NHL) - Leukemia (ALL, AML, CLL, CML) - Multiple myeloma - MDS - Myelofibrosis - Myeloproliferative disease (Thrombocytosis, Polycythemia) - Neutropenia
Red blood cells
Anemia - Hemochromatosis - Sickle-cell anemia - Thalassemia - G6PD - other hemoglobinopathies
Coagulation and Platelets
Thrombosis - Deep venous thrombosis - Pulmonary embolism - Hemophilia - ITP - TTP

  Results from FactBites:
 
US FDA/CDRH: FDA Statement on Coronary Drug-Eluting Stents (986 words)
Stent thrombosis in patients who receive DES is a primary area of interest for the agency because of the potential for serious adverse outcomes—even though stent thrombosis occurs at low rates.
The CYPHER Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length ≤ 30 mm in native coronary arteries with reference vessel diameter of ≥2.5 mm to ≤3.5 mm.
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions ≤28 mm in length in native coronary arteries ≥2.5 to ≤3.75 mm in diameter.
InfraReDx - new insight into Coronary Artery Disease (399 words)
Such plaques, which cannot be detected by commonly-used tests such as a treadmill examination and even coronary angiography, are suspected to be the cause of most sudden cardiac deaths and non-fatal heart attacks.
Coronary artery disease is the leading cause of death in developed nations.
The cause of most heart attacks is rupture of a plaque in the coronary arteries followed by formation of a clot that blocks the flow of blood to heart muscle.
  More results at FactBites »

 
 

COMMENTARY     


Share your thoughts, questions and commentary here
Your name
Your comments

Want to know more?
Search encyclopedia, statistics and forums:

 


Press Releases |  Feeds | Contact
The Wikipedia article included on this page is licensed under the GFDL.
Images may be subject to relevant owners' copyright.
All other elements are (c) copyright NationMaster.com 2003-5. All Rights Reserved.
Usage implies agreement with terms, 1022, m